Efficacy and safety of Achillea wilhelmsii C. Koch capsules on symptom severity and quality of life in patients with irritable bowel syndrome: a randomized, placebo-controlled clinical trial

References

[1] Kong SC, Hurlstone DP, Pocock CY, Walkington LA, Farquharson NR, Bramble MG, et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005;39:138–41.Search in Google Scholar PubMed

[2] Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107:991.10.1038/ajg.2012.131Search in Google Scholar PubMed

[3] Patrick DL, Drossman DA, Frederick IO, Dicesare J, Puder KL. Quality of life in persons with irritable bowel syndrome (development and validation of a new measure). Dig Dis Sci 1998;43:400–11.10.1023/A:1018831127942Search in Google Scholar PubMed

[4] Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402.10.1046/j.1365-2036.1997.142318000.xSearch in Google Scholar PubMed

[5] Borgaonkar M, Irvine E. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000;47:444–54.10.1136/gut.47.3.444Search in Google Scholar PubMed PubMed Central

[6] Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 2004;94:161–5.10.1254/jphs.94.161Search in Google Scholar PubMed

[7] Drossman DA, Whitehead W, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterol 1997;112:2120–37.10.1053/gast.1997.v112.agast972120Search in Google Scholar PubMed

[8] Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol: WJG 2009;15:1548.10.3748/wjg.15.1548Search in Google Scholar PubMed PubMed Central

[9] Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil 2016;22:558.10.5056/jnm16001Search in Google Scholar PubMed PubMed Central

[10] Davis K, Philpott S, Kumar D, Mendall M. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int J Clin Pract 2006;60:1080–6.10.1111/j.1742-1241.2006.00980.xSearch in Google Scholar PubMed

[11] Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010;55:1385–90.10.1007/s10620-009-0854-9Search in Google Scholar PubMed

[12] Rahimi R, Abdollahi M. Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol: WJG 2012;18:589.10.3748/wjg.v18.i7.589Search in Google Scholar PubMed PubMed Central

[13] Majnooni M, Mohammadi-Farani A, Gholivand M, Nikbakht M, Bahrami G. Chemical composition and anxiolytic evaluation of Achillea Wilhelmsii C. Koch essential oil in rat. Res Pharm Sci 2013;8:269.Search in Google Scholar PubMed

[14] Saeidnia S, Gohari A, Mokhber-Dezfuli N, Kiuchi F. A review on phytochemistry and medicinal properties of the genus Achillea. DARU 2011;19:173.Search in Google Scholar PubMed

[15] Tosun F, Kızılay ÇA, Şener B, Vural M, Palittapongarnpim P. Antimycobacterial screening of some Turkish plants. J Ethnopharmacol 2004;95:273–5.10.1016/j.jep.2004.07.011Search in Google Scholar PubMed

[16] Khorasani MA. Makhzan al Advieh. Tehran. Iran: Bavardaran Press. Research institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, 2001.Search in Google Scholar

[17] Aghili MH. Gharabadin kabir. Tehran: Research Institute for Islamic and Complementary Medicine, 2008.Search in Google Scholar

[18] Ali N, Shah SW, Ahmed G, Shah I, Shoaib M, Junaid M, et al. Acute toxicity and antispasmodic activities of Achillea wilhelmsii C. Koch. Pak J Pharm Sci 2014;27:309–15.Search in Google Scholar PubMed

[19] Boskabady MH, Eftekhar N, Kaveh M. Possible mechanism (s) of the relaxant effects of Achillea wilhelmsii on Guinea-Pig Tracheal chains. Iran J Pharm Res 2013;12:381.Search in Google Scholar PubMed

[20] Bashi DS, Fazly Bazzaz BS, Sahebkar A, Karimkhani MM, Ahmadi A. Investigation of optimal extraction, antioxidant, and antimicrobial activities of Achillea biebersteinii and A. wilhelmsii. Pharm Biol 2012;50:1168–76.10.3109/13880209.2012.662235Search in Google Scholar PubMed

[21] Sharifi-Rad J, Mnayer D, Roointan A, Shahri F, Ayatollahi S, Sharifi-Rad M, et al. Antibacterial activities of essential oils from Iranian medicinal plants on extended-spectrum β-lactamase-producing Escherichia coli. Cell Molecul Biol 2016;62:75–82.Search in Google Scholar

[22] Alfatemi S, Rad J, Rad M, Mohsenzadeh S, Da Silva J. Chemical composition, antioxidant activity and in vitro antibacterial activity of Achillea wilhelmsii C. Koch essential oil on methicillin-susceptible and methicillin-resistant Staphylococcus aureus spp. 3 Biotech 2014;5:39–4410.1007/s13205-014-0197-xSearch in Google Scholar PubMed PubMed Central

[23] Kazemi M, Rostami H. Chemical composition and biological activities of Iranian Achillea wilhelmsii L. essential oil: a high effectiveness against Candida spp. and Escherichia strains. Nat Prod Res 2015;29:286–8.10.1080/14786419.2014.953949Search in Google Scholar PubMed

[24] Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterol 2006;130:1377–90.10.1053/j.gastro.2006.03.008Search in Google Scholar PubMed

[25] Alt F, Chong PW, Teng E, Uebelhack R. Evaluation of benefit and tolerability of IQP-CL-101 (Xanthofen) in the symptomatic improvement of irritable bowel syndrome: a double-blinded, randomised, Placebo-controlled clinical trial. Phytother Res 2017;31:1056–62.10.1002/ptr.5826Search in Google Scholar PubMed PubMed Central

[26] Khazneh E, Hřibová P, Hošek J, Suchý P, Kollár P, Pražanová G, et al. The chemical composition of Achillea wilhelmsii C. Koch and its desirable effects on hyperglycemia, inflammatory mediators and hypercholesterolemia as risk factors for cardiometabolic disease. Molecules 2016;21:404.10.3390/molecules21040404Search in Google Scholar PubMed PubMed Central

[27] Niazmand S, Khooshnood E, Derakhshan M. Effects of Achillea wilhelmsii on rat’s gastric acid output at basal, vagotomized, and vagal-stimulated conditions. Pharmacog Mag 2010;6:282.10.4103/0973-1296.71791Search in Google Scholar PubMed PubMed Central

[28] Stojanovic G. Experimental study of the effect of the phytomixture made of leaves of Plantago major L. and Achillea millenfolium L. on the secretion activity of the stomach in dogs. Eksp Klin Gastroenterol 2005;4:73–6.Search in Google Scholar

[29] Santos FA, Rao VS. 1, 8-cineol, a food flavoring agent, prevents ethanol-induced gastric injury in rats. Dig Dis Sci 2001;46:331–7.10.1023/A:1005604932760Search in Google Scholar PubMed

[30] Kazemian A, Toghiani A, Shafiei K, Afshar H, Rafiei R, Memari M, et al. Evaluating the efficacy of mixture of Boswellia carterii, Zingiber officinale, and Achillea millefolium on severity of symptoms, anxiety, and depression in irritable bowel syndrome patients. J Res Med Sci 2017;22:12010.4103/jrms.JRMS_905_16Search in Google Scholar PubMed PubMed Central

[31] Lu CL, Chang FY. Placebo effect in patients with irritable bowel syndrome. J Gastroenterol Hepatol 2011;26:116–18.10.1111/j.1440-1746.2011.06651.xSearch in Google Scholar PubMed

[32] Smart H, Mayberry J, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut 1986;27:826–8.10.1136/gut.27.7.826Search in Google Scholar PubMed PubMed Central

[33] Asadi-Shahmirzadi A, Mozaffari S, Sanei Y, Baeeri M, Hajiaghaee R, Monsef-Esfahani HR, et al. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: combination of antioxidant and spasmolytic effects. Chin J Integr Med 2012;1–9.10.1007/s11655-012-1027-9Search in Google Scholar PubMed

[34] Babish JG, Howell TM, Pacioretty LM. Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2. Google Patents 2007.Search in Google Scholar

[35] Patel S, Stason W, Legedza A, Ock S, Kaptchuk T, Conboy L, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332–40.10.1111/j.1365-2982.2005.00650.xSearch in Google Scholar PubMed

[36] Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech 2015;16:731–41.10.1208/s12249-015-0350-9Search in Google Scholar PubMed PubMed Central